TrialHaematologica2018

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.

Véronique Leblond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.